For anyone impacted by type 1 diabetes (T1D), the term ‘biosimilars’ is one that will become increasingly familiar now that the patents of some biologic insulins are expiring. This means that biosimilar versions of these insulins may be approved, and some are already on the North American market.
Monitoring Your Child’s Glucose Remotely
Like most parents after their child has been diagnosed with Type 1 diabetes, Cindy Voss found herself overwhelmed, anxious and exhausted. With an active 10-year old whose glucose levels would drop quickly and unexpectedly, Cindy found herself constantly worrying and would get up every couple of hours throughout the night to prick her son Mathew’s finger to get a blood sugar reading.
Ustekinumab, A Potentially Disease Modifying Drug for Type 1 Diabetes, Is Being Tested in Clinical Trials in Canada
A JDRF-funded clinical trial is examining whether a drug currently (ustekinumab; pronounced oos·teh·KIN·yoo·mab) used for the treatment of psoriasis (which affects the skin), Crohn’s disease (an inflammatory bowel disease), and other autoimmune conditions can also work for type 1 diabetes.
JDRF Advocacy Efforts to Ensure COVID-19 Vaccination Priority for the Type 1 Diabetes Community
We’ve received many questions about the COVID-19 vaccination rollout in provinces and territories across Canada, and specifically at what stage people living with type 1 diabetes (T1D) should expect to receive theirs.
Exciting new updates in JDRF funded research of Sernova’s Cell Pouch System
On January 15, 2021 Sernova announced that patients in their ongoing clinical trial show persistent islet function and clinically meaningful improvement in glucose control.
JDRF Canada recognizes #BellLetsTalk
January 28, 2021 marks this year’s #BellLetsTalk day. This provides us the opportunity to talk freely and safely about mental health issues, and to raise awareness of the challenges faced by people living with T1D daily – and how JDRF Canada is looking to do more to address mental health in this community.
Monsters Are Real
JDRF Canada has a plan to defeat the T1D monster that burdens 300,000 Canadians.
Simplifying insulin management and delivery
For years, Rebecca Redmond’s mantra was to “stick to the devil you know” when managing her type 1 diabetes (T1D). That meant injecting herself with insulin numerous times a day, even after developing a phobia of needles, resulting in debilitating anxiety attacks and sometimes even forgoing meals.
Your fundraising dollars at work
Here are the top 2020 JDRF-funded research projects.
Navigating the Holidays with T1D during COVID
With the holiday season quickly approaching, it’s time to start thinking about shopping lists, holiday plans with friends and family members, and how to keep our children active during their time off from school, while adhering to the safety measures influenced by the global pandemic. We’ve provided some helpful tips to help you stay safe and healthy during the holiday season.
COVID-19 Vaccines and T1D
JDRF welcomes the authorization of the first COVID-19 vaccine by Health Canada, which we hope will be one of many to be approved in the coming months to address the pandemic. We are grateful for the unprecedented effort by the many research scientists, clinical trial participants, industry partners and government officials who contributed to global efforts to rapidly bring COVID-19 vaccines through the pipeline and to our communities.
COVID-19 and Type 1 Diabetes – What We Know Now
Protecting yourself from the virus on top of everyday diabetes management is a lot to deal with.
Fortunately, we are now better equipped with knowledge of how the virus works and how to best protext ourselves from contracting it. And there is hope on the horizon.